Rose Bengal ALS Therapy for SOD1 and TDP-43 Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no cure for amyotrophic lateral sclerosis (ALS), and existing treatments only provide symptomatic relief, with no disease-modifying therapies available to address the aggregation of proteins like SOD1 and TDP-43 that contribute to the progression of the disease.
Innovation Solution
A pharmaceutical composition containing rose bengal compounds is used to inhibit the aggregation of SOD1 and TDP-43 by blocking RNA binding to the RRM1/2 interface, interacting with the CTD region of TDP-43, stabilizing the SOD1 dimer, and inhibiting aggregation of wild-type and mutant SOD1, thereby preventing the formation of insoluble aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current symptomatic relief treatments are used for ALS, then patient comfort is improved, but disease progression is not halted and mortality remains high
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that bind to RNA at the RRM1/2 interface, preventing RNA from binding to TDP-43 and stabilizing the SOD1 dimer. This intermediary action blocks the aggregation pathway of both TDP-43 and SOD1 proteins, providing disease-modifying effects beyond mere symptomatic relief
Solution Approach 2:
The patent employs compounds that alter the binding parameters between RNA and TDP-43, and between subunits of the SOD1 dimer. By changing these molecular interaction parameters, the compounds prevent protein aggregation and stabilize normal protein function, addressing the root cause of disease progression
2Device complexity
If no disease-modifying therapy is available, then treatment simplicity is maintained, but protein aggregation continues unchecked leading to neurodegeneration
Solution Approach 1:
The patent extracts and targets the specific molecular interactions that drive protein aggregation - namely the RNA-TDP-43 binding at the RRM1/2 interface and the dimer-subunit interactions in SOD1. By taking out these critical binding events and blocking them with small molecules, the harmful aggregation process is interrupted
Solution Approach 2:
The patent employs composite therapeutic compounds that simultaneously target multiple pathological mechanisms - blocking RNA binding to TDP-43 while also stabilizing SOD1 dimer structure. This multi-target composite approach addresses both major protein aggregation pathways in ALS with a single treatment regimen
3Stability of the object's composition
If SOD1 dimer stability is not maintained, then natural protein turnover is preserved, but de-metalated monomers aggregate into toxic insoluble inclusion bodies
Solution Approach 1:
The patent applies preliminary stabilizing action to the SOD1 dimer before dissociation and aggregation can occur. The small molecule compounds bind to and stabilize the dimer structure, preventing the sequence of events that leads to de-metalation, monomer formation, and subsequent aggregation into toxic inclusions
Solution Approach 2:
The patent provides beforehand protection by stabilizing the SOD1 dimer structure prior to any destabilizing events. This preemptive stabilization cushions against the formation of de-metalated monomers and their subsequent aggregation, preventing toxic aggregate formation before it can occur
Data Source
AI summary
The present invention is directed to a pharmaceutical composition and method for treating a subject diagnosed amyotrophic lateral sclerosis (ALS) with a pharmaceutical composition containing dissolved or dispersed therein a SOD1 and/or TDP-43 aggregation-inhibiting amount of a rose bengal (RB) compound that is a pharmaceutically acceptable salt of RB, RB lactone, a RB amide, an aromatic RB derivative, wherein the aromatic derivative is an ester or amide formed from an alcohol or monosubstituted amine having a 5- or 6-membered aromatic ring, or a 5,6- or 6,6-fused aromatic ring system that contains 0, 1, or 2 hetero ring atoms that are independently nitrogen, oxygen or sulfur. This treatment method is typically repeated a plurality of times or until the subject no longer needs it.